Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. - Freet CS; Shuler K; Kawasaki S; Weintraub E; Greenblatt A; Kladney M; Nunes E; Foster KL; Kong L; Raja-Khan N; Cleveland HH; Grigson PS; et al. (Research square, 2025)